Dr. Steven Burrell
Dr. Steven Burrell is a Nuclear Medicine physician at the QEII Health Sciences Centre and a Professor of Radiology at Dalhousie University in Halifax Nova Scotia. After an initial career in engineering, he completed medical school and residencies in radiology and nuclear medicine at Dalhousie University, and a fellowship in nuclear medicine at Harvard University. His clinical and research interests include imaging of osteoporosis, cancer, and heart disease. He chaired the committee developing the 2024 Canadian Association of Radiologists Bone Mineral Density reporting guideline. With Osteoporosis Canada he is a member of the Scientific Advisory Council and the Diagnostic Imaging Knowledge Translation committee, and was a member of the committee developing the 2023 clinical practice guideline. He is currently chair of the Canadian panel of the International Society of Clinical Densitometry.
Dr. Angela Cheung
Dr. Angela M. Cheung is Professor of Medicine, KY and Betty Ho Chair in Integrative Medicine at University of Toronto and Senior Physician Scientist at University Health Network. She is the Founding Director of the Osteoporosis Program at University Health Network and the Founding Director of the Centre of Excellence in Skeletal Health Assessment at University of Toronto. She obtained her MD from Johns Hopkins University in 1988 and her PhD from Harvard University in 1997. She is a Fellow of the Royal College of Physicians of Canada and has been in clinical practice for >30 years.
She has won many research, teaching and mentorship awards over the years, including the 2024 ASBMR Gideon Rodan’s Mentorship Award, the 2023 European Calcified Tissue Society (ECTS) Research Excellence Award, Canadian Institutes of Health Research (CIHR) Senior Investigator award, Canadian Society of Internal Medicine (CSIM) Dr. David Sackett Senior Investigator Award, Ontario Premier Research Excellence Award, University of Toronto (U of T) Eaton Scholar Award in Clinical Research, University Health Network (UHN) Excellence in Clinical Teaching award, U of T Eudenie Stuart Mentorship award and UHN/Sinai Health System Michael Hutcheon Mentorship award. She currently holds a Tier 1 Canada Research Chair in Postmenopausal and Musculoskeletal Health.
Dr. Cheung joins the Canadian Osteogeneis Imperfecta Society (COIS) as the Medical Advisor and Chair of the COIS Medical Advisory Committee. She was the past chair of Osteoporosis Canada Scientific Advisory Council. She is a current member of the International Osteoporosis Foundation Council of Scientific Advisors and the President for International Society of Clinical Densitometry. She has published over 250 peer-reviewed manuscripts and has a h-index of 75. Her research interests are in postmenopausal osteoporosis, atypical femur fractures and rare bone diseases.
Dr. Tyler Churchward‑Venne
Dr. Tyler Churchward‑Venne is an Associate Professor in the Department of Kinesiology and Physical Education at McGill University in Montreal, Canada. He is a William Dawson Scholar and directs the Exercise Metabolism, Nutrition, and Muscle Health Lab. He joined McGill in 2018 following postdoctoral training at Maastricht University in the Netherlands, where he was a Marie Skłodowska‑Curie Fellow.
Dr. Churchward‑Venne’s research focuses on skeletal muscle health, particularly the role of nutrition and exercise in regulating muscle protein metabolism. His lab uses a wide range of techniques—including stable isotope tracers, magnetic resonance imaging, and molecular biology tools—to investigate muscle protein turnover and the mechanisms underlying muscle adaptation.
A major emphasis of his work is on understanding and mitigating muscle loss due to aging or muscle disuse, such as during bed rest. His research explores how nutritional strategies—especially dietary protein intake—can be optimized in conjunction with exercise to preserve or restore muscle mass, function, and metabolic health. His lab is also evaluating novel interventions, such as exogenous ketone supplements, as potential protective agents during periods of inactivity.
Dr. Churchward‑Venne has received funding from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), Muscular Dystrophy Canada, and the Canada Foundation for Innovation (CFI), among others. In recognition of his contributions to the field, he received the Peter J. Reeds Young Investigator Award from the American Society for Nutrition in 2019.
In addition to leading his research program, Dr. Churchward‑Venne is a member of McGill’s Division of Geriatric Medicine and an Investigator at the Research Institute of the McGill University Health Centre.
Dr. Cathy Craven
Dr. Craven is the University of Toronto/University Health Network (UHN), Cope Family Chair in Spinal Cord Injury (SCI) Rehabilitation Health Systems Innovations, Medical Director of the Spinal Cord Rehabilitation Program, Executive Lead of the Pride in Patient Engagement in Research (PiPER) portfolio at UHN, and Senior Scientist/Neural Engineering and Therapeutics Team Co-Lead at KITE Research Institute. Dr. Craven is a Professor and Clinician Scientist in the Division of Physical Medicine and Rehabilitation, Department of Medicine, Temerty Faculty of Medicine, at the University of Toronto. Her clinical and research expertise is in health services & systems and the medical rehabilitation of sublesional osteoporosis to avoid fractures. Dr. Craven is the Quality Leader of the SCI Implementation and Evaluation Quality Care Consortium.
Dr. Craven Is a Fellow of the Canadian Academy of Health Sciences (2021) and American Spinal Injury Association (2019) and a Canadian Association of PM&R Award of Merit winner (2017).
Outside of work, Dr. Craven chairs the Canadian Spinal Cord Injury – Rehabilitation Association and serves on the Ontario SPOR (Strategy for Patient Oriented Research) Support Unit Board of Directors.
Dr. Craven has published 260+ peer-reviewed articles, with an h-index of 56, and over 11,000 citations of her work. She has secured over $32M in PI research funding. For more information about her research, visit her lab website: www.cravenlab.ca
For full publication list see:
https://www.ncbi.nlm.nih.gov/myncbi/beverley.craven.1/bibliography/public/
Dr. Gustavo Duque
Dr. Gustavo Duque, MD, Ph.D., FRACP, FGSA is a geriatrician and biomedical scientist with a research interest in the mechanisms, potential therapies, and biomarkers for age-related bone loss, osteoporosis, sarcopenia, osteosarcopenia, and frailty in older persons. He is also studying the effect of vitamin D, exercise, protein and nutraceuticals on bone and muscle mass.
His initial training included Internal Medicine at Javeriana University (Colombia) and Geriatric Medicine, which he completed at McGill University in Montreal (Canada). Subsequently, he obtained his Ph.D. at McGill University in 2003 with a thesis entitled ‘Molecular Changes of the Aging Osteoblast’ under the supervision of Dr. Richard Kremer. Between 2003 and November 2007, he joined the McGill University Medical School faculty as a member of the Division of Geriatric Medicine and as a Researcher at the Lady Davis Institute for Medical Research. In November 2007, he moved to Australia to join the Faculty as Associate Professor and Head of the Division of Geriatric Medicine and Director of the Musculoskeletal Ageing Research Program at Sydney Medical School Nepean -University of Sydney. In 2012, he was promoted to Professor of Medicine at the University of Sydney. Between 2015 and 2022, Dr. Duque was Chair of Medicine and Director of the Australian Institute for Musculoskeletal Science at the University of Melbourne.
In 2022, Dr. Duque assumed the roles of Full Professor, Dr. Joseph Kaufmann Chair in Geriatric Medicine, Director – RUISSS McGill Centre of Excellence for Sustainable Health of Seniors/ Simone & Edouard Shouela (CEDurable), and Principal Investigator at the Bone, Muscle & Geroscience Group of the Research Institute of the McGill University Health Centre (MUHC). He is the Editor-in-Chief of the Journal of Gerontology: Biological Sciences, one of the official journals of the Gerontological Society of America. He is also the Chair of the recently created Canadian Translational Geroscience Network.
As a Geriatrician and Clinician-Investigator, Dr. Duque has implemented several Falls and Fractures clinics (the most recent ones at the MUHC and the Jewish General Hospital in Montreal) where patients are comprehensively assessed for falls and fracture risk. His clinical trials unit conducts several trials testing the effect of pharmacological and non-pharmacological treatments for age-related musculoskeletal diseases. He is the author of more than 300 peer-reviewed articles and multiple book chapters and has edited five books in the aging and musculoskeletal fields.
Dr. Raymond Fung
Dr. Raymond Fung completed his residency and subspecialty training in Endocrinology at the University of Toronto. He has been practicing at Michael Garron Hospital since 2006, where he currently serves as Head of the Division of Endocrinology. Dr. Fung has a special interest in transgender health and is actively involved in resident education and research initiatives focused on trans care.
Dr. Claudia Gagnon
Dr. Claudia Gagnon is an adult endocrinologist at CHU de Québec-Université Laval and full professor in the Department of Medicine at Université Laval. She is also a researcher at CHU de Québec-Université Laval Research Centre and at the Québec Heart and Lung Institute Research Centre in Québec City. After completing residency training in adult endocrinology, she undertook a 3-year fellowship in metabolic bone diseases and phosphocalcic metabolism in Melbourne, Australia.
A large part of her clinical practice focuses on the treatment of osteoporosis, metabolic bone diseases and disorders of phosphocalcic metabolism. Her main research interests are on the impact of obesity, diabetes, and bariatric surgery on bone health.
She received funding from Diabetes Canada, Diabète Québec, and the Canadian Institutes of Health Research. She published several articles in peer-reviewed journals, some of which were cited in the most recent bone guidelines of the American Society for Bariatric and Metabolic Surgery. She has been awarded the 2022 Canadian Society of Endocrinology and Metabolism Young Investigator Award, the 2019 Jean-Davignon Young Investigator Award from the Cardiometabolic, diabetes and obesity FRQ-S network, the 2017 research prize of the Fédération des médecins spécialistes du Québec, and the 2015 New Investigator Award at the International Symposium on the Nutritional Aspects of Osteoporosis.
She has been the Vice-Chair of the Scientific Advisory Council of Osteoporosis Canada from 2021-2024 and sits on the Board of Directors of Osteoporosis Canada since 2023. She is actively involved within the Osteoporosis Canada Scientific Advisory Council (Musculoskeletal Conference, rapid response team, knowledge transfer diagnostic imaging subcommittee, beyond the break presentations, podcasts). She is also actively involved in various provincial and national committees including Diabète Québec, Diabetes Canada, and INESSS. Finally, she has been involved in the international guidelines on vitamin D supplementation after bariatric surgery and X-linked hypophosphatemic rickets.
Dr. Lora Giangregorio
Dr. Lora Giangregorio, PhD is a Professor and Tier 1 Canada Research Chair in Bone Health and Exercise Science in the Department of Kinesiology and Health Sciences at the University of Waterloo. She leads the Bone Health and Exercise Science Lab, or BonES lab. The BonES lab team leads research on physical activity for fall and fracture prevention. Dr. Giangregorio is a member of the Scientific Advisory Council for Osteoporosis Canada and was on the leadership team that developed the 2020 Canadian 24-hour Movement Guidelines. She also led the Exercise Working Group for the 2023 Clinical Practice Guidelines for Management of Osteoporosis and Fracture Prevention in Canada.
Dr. Famida Jiwa
Dr. Jiwa is the President and CEO of Osteoporosis Canada, and has been with the organization since 2006. Prior to joining Osteoporosis Canada, Dr. Jiwa was the former Provincial Osteoporosis Co-ordinator, employed by the Ontario Ministry of Health and Long Term Care and charged with rolling out all aspects of the $5 million annual Ontario Osteoporosis Strategy. Prior to this and after leaving her private practice in Orlando, Florida, Dr. Jiwa was a Program Consultant for the Acute Services Division of the Ministry of Health, where she played a significant role in project planning, implementation and evaluation of a number of provincial health initiatives, including chronic kidney disease, asthma and age-related macular degeneration.
In 2020 Dr. Jiwa was elected to the Board of Directors of the International Osteoporosis Foundation, representing North America, for a term of 4 years. She also serves as the chair of the Patient Societies Subcommittee of the Committee of National Societies (CNS) of the International Osteoporosis Foundation (IOF). In 2020, Dr. Jiwa was awarded the CNS Medal from the International Osteoporosis Foundation. In 2016, she was awarded the President’s Award from the International Osteoporosis Foundation. She is also the recipient of the Queen Elizabeth II Diamond Jubilee Medal. Dr. Jiwa has also attained the designation of Certified Health Executive from the Canadian College of Health Leaders, and in 2017 she completed the Strategic Perspectives in Nonprofit Management program at Harvard Business School.
She holds a Masters Degree in Health Administration from the Department of Health Policy, Management and Evaluation from the University of Toronto, a Doctorate of Chiropractic from the Canadian Memorial Chiropractic College in Toronto, as well as an Honours Bachelor of Science, Genetics and Psychology from the University of Toronto.
Dr. Aliya Khan
Dr. Aliya Khan is a Clinical Professor of Medicine , Division of Endocrinology and Geriatrics, Director of the Calcium Disorders Clinic, and Director of the Fellowship in Metabolic Bone Disease at McMaster University. She graduated from the University of Ottawa Medical School with honors. She trained in Internal Medicine, Geriatric Medicine and Endocrinology and completed a fellowship in Metabolic Bone Disease at the University of Toronto. She has published over 400 scientific papers and numerous chapters and books on osteoporosis and parathyroid disease.
She led the development of global guidelines for parathyroid disease, osteonecrosis of the jaw, new diagnostic criteria for hypophosphatasia, treatment guidelines for X-linked hypophosphatemia in addition to osteoporosis guidelines. She is the co-chair of the International Working Group developing best practice recommendations on bone mineral density reporting supported. She is a leading clinician researcher and is the principle investigator evaluating novel therapies for parathyroid disease including PTH , PTH analogues as well PTH1receptor agonists for hypoparathyroidism.
She has received numerous international awards for outstanding contributions to Medicine including the Queen’s Diamond Jubilee Medal , International Osteoporosis Foundation award , Osteoporosis Canada Lindy Fraser award, Woman Physician of the Year Award by the American College of Physicians, Canadian Society of Endocrinology and Metabolism Dr. Jacques Genest Lecture Award. ORTOMED Medal from the Italian Society of Orthopedics and Medicine, King Charles Coronation medal and 2025 American Association of Clinical Endocrinologists Outstanding International Clinician award.She is recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape.
Dr. Sandra Kim
Dr. Sandra Kim is an Associate Professor and Clinician Teacher in Department of Medicine and Division of Endocrinology & Metabolism at the University of Toronto. She is the Division Head of Endocrinology at Women’s College Hospital and past Director of the Osteoporosis Program. Her clinical and academic focus is on osteoporosis and metabolic bone disease. She was the past chair of the Scientific Advisory Council for Osteoporosis Canada and the current chair of their guidelines committee. She led the pharmacotherapy working group for the 2023 Canadian Osteoporosis Clinical Practice Guideline update and serves on the Canadian Panel for the International Society for Clinical Densitometry. Dr. Kim is actively involved in teaching at both the undergraduate and postgraduate levels and is the recipient of several awards. She is also involved with the Ontario Osteoporosis Strategy in providing osteoporosis care to under-serviced communities via telemedicine.
Dr. Adrian Lau
Dr. Adrian Lau completed his medical training at the University of Toronto and is currently an endocrinologist at Women’s College Hospital. He is an Assistant Professor of Medicine at the University of Toronto and is active with medical education at both the undergraduate and postgraduate levels. Dr. Lau is the vice-chair of Osteoporosis Canada’s Scientific Advisory Council (SAC), serves as the medical advisor of the Canadian Osteoporosis Patient Network (COPN), and chairs Osteoporosis Canada’s Rapid Response Committee.
Dr. Laëtitia Michou
Dr Laëtitia Michou, MD, PhD is an associate professor and head of the Division of Rheumatology at CHU de Québec-Université Laval. Dr Michou is a clinical investigator at the Centre de Recherche du CHU de Québec and rheumatologist at the CHU de Québec. Research interests of Dr. Michou are human genetics of bone and joint diseases, particularly Paget’s disease of bone, rare bone diseases, osteoporosis, atypical femur fractures and rheumatoid arthritis. In career, Dr Michou has published 81 refereed publications and more than 150 conference abstracts. She has supervised research projects of 70 undergraduate, graduate, or medicine students or residents from four continents.
Dr. Michou has completed her medicine training, rheumatology residency, and PhD in Human Genetics in France. She had completed a clinical fellowship of two years in fragility bone diseases at the centre Viggo Petersen, Rheumatology department, Lariboisière hospital, Assistance publique-Hôpitaux de Paris, France.
Dr Michou is a member of the scientific advisory committee of Osteoporosis Canada since 2012, member of the research committee from 2016 to 2023, member of the board of directors and chair of the scientific advisory council since September 2024.
Dr. Rowena Ridout
Dr. Ridout is an endocrinologist at Toronto Western Hospital where her clinical practice focuses on osteoporosis and pituitary disease. She is the past chair of the Scientific Advisory Council for Osteoporosis Canada, and was a member of the Pharmacotherapy working group for the 2023 Osteoporosis Canada Clinical Practice Guideline Update. She is actively involved in teaching at the undergraduate and postgraduate levels.
Dr. Cheryl Rockman-Greenberg
Dr. Cheryl Rockman- Greenberg obtained her MD, CM degree from McGill University in 1974. She became a Fellow of the Royal College of Physicians and Surgeons of Canada (Pediatrics) in 1979 and in Medical Genetics in 1996. She has been a Fellow of the Canadian College of Medical Geneticists since 1982. Dr. Rockman-Greenberg served as Medical Director of the Child Health program, WRHA, and Head of the Department of Pediatrics and Child Health, University of Manitoba, from 2004-2014. Dr. Rockman-Greenberg has practiced as a clinical and metabolic geneticist in Winnipeg since 1979.
She is currently a clinician scientist in the Children’s Hospital Research Institute of Manitoba (CHRIM) and holds the academic rank of Distinguished Professor in the Departments of Pediatrics & Child Health and Biochemistry & Medical Genetics, University of Manitoba. The contributions of Dr. Rockman- Greenberg to the continuum of science start with clinical problems, establishing relationships with families and unique communities and working to translate discoveries into effective patient care programmes. Dr. Rockman-Greenberg was named to the 2012 list of Canada’s Most Powerful Women: Top 100, in the Trailblazers and Trendsetters category and she received the Founders Awards for Excellence in Medical Genetics from the Canadian College of Medical Geneticists (CCMG) in 2017.
She was inducted into the Canadian Medical Hall of Fame in April 2018 for Leadership in Health Promotion, Illness Prevention and Care and into the Order of Manitoba in July 2018. In December 2020 she was appointed to the Order of Canada as an Officer and in May 2021 she was the recipient of the Pioneer Award from the Garrod Association of Canada.
Dr. Sonia Singh
Dr. Sonia Singh is a hospitalist physician and osteoporosis consultant based at Peace Arch Hospital in White Rock, British Columbia (BC), Canada. She is the medical lead for BC’s first Fracture Liaison Services (FLS) since 2015 and is currently Osteoporosis Canada (OC)’s National FLS Implementation Lead. She has been the principal investigator on a number of research grant awards provincially and nationally in the area of osteoporosis and fracture prevention and is supported by a Health Research BC 5-year health professional investigator award (2024-2029). She has received a number of awards including a 2015 Fraser Health Above and Beyond Award for Evidence-based Practice, a 2022 Community BackBone Award from OC and a 2024 International Women’s Day award from Fraser Health.
Dr. Singh is a Clinical Assistant Professor, Faculty of Medicine, University of BC and Adjunct Professor, Faculty of Health Sciences, Simon Fraser University. In addition, she is the co-chair of the BC Coalition of Osteoporosis Physicians FLS Special Interest Group and the past co-chair (2022-2025) of the Fragility Fracture Network Special Interest Group in Secondary Fracture Prevention.
Dr. Lianne Tile
Dr. Lianne Tile is a general internal medicine specialist and clinician teacher at University Health Network and Mount Sinai Hospital in Toronto. She holds an MD degree from Queen’s University, and she completed residency training in internal medicine at Queen’s University and the University of Toronto. She is medical director of the UHN Osteoporosis Clinic. She has clinical and research expertise in osteoporosis, atypical femur fractures, and rare bone diseases.